<DOC>
	<DOCNO>NCT01049022</DOCNO>
	<brief_summary>The purpose study describe pharmacokinetics moxifloxacin child see best dose child future . Pharmacokinetics see body absorbs , distributes , break get rid study drug . The pharmacokinetics certain drug may alter child due developmental difference various organ function responsible drug elimination , well general distribution characteristic . The safety moxifloxacin child infection also look . Results study use guide dose strategy large clinical trial plan child</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetics Single Dose Intravenous Moxifloxacin Pediatric Patients</brief_title>
	<detailed_description />
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Males female , age 3 month 14 year inclusive Receiving antibiotic suspect proven infection Body weight great 45 kg Patients take antiseizure medication within 30 day moxifloxacin dose Known suspect allergy quinolones History tendon disease/disorder relate quinolone treatment Severe , lifethreatening disease life expectancy le 48 hour and/or know rapidly fatal underlying disease ( death expect within 2 month ) Abnormal musculoskeletal evaluation baseline assessment ; chronic musculoskeletal disease ( eg , juvenile rheumatoid arthritis ) ; chronic illness high risk chronic recurrent arthritis tendinitis ( eg , cystic fibrosis , chronic inflammatory bowel disease ) Cardiac arrhythmia Evidence renal hepatic disease , base laboratory finding ( serum creatinine , total bilirubin , ALT , &gt; 1.5 time upper limit normal ) physical exam Patients receive Class IA ( e.g. , quinidine , procainamide ) Class III ( e.g. , amiodarone , sotalol ) antiarrhythmic agent Patients take medication know increase QT interval , eg , amiodarone , astemizole , bepridil , chloroquine , chlorpromazine , cisapride , disopyuramide , dofetilide , droperidol , halofantrine , haloperidol , ibutilide , levomethadyl , mesoradazine , methadone , pimozide , procainamide , quinidine , sotalol , terfenadine Pregnancy Clinically relevant finding ECG Participation another clinical study precede 30 days1 ( last treatment previous study first treatment new study ) Criteria opinion investigator preclude participation scientific reason , reason compliance , reason patient 's safety Patients take another fluoroquinolone time plan moxifloxacin dose</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Pharmacokinetics</keyword>
</DOC>